Back to top
more

Hologic (HOLX)

(Delayed Data from NSDQ)

$80.24 USD

80.24
1,245,584

+1.02 (1.29%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $80.25 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (61 out of 252)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Penumbra (PEN) Q1 Loss Wider than Expected, View Intact

Penumbra, Inc. (PEN), that went public in Sep 2015, reported first-quarter 2017 loss of 10 cents per share, comparing unfavorably with earnings of 7 cents year over year.

    PetMed (PETS) Beats Earnings, Revenue Estimates in Q4

    PetMed Express, Inc. (PETS) announced earnings per share of 37 cents for the fourth quarter of fiscal 2017, up 37% from the year-ago quarter's 27 cents.

      Henry Schein (HSIC) Tops Q1 Earnings, Reaffirms '17 View

      Henry Schein, Inc. (HSIC) reported adjusted earnings per share (EPS) of $1.76 in the first quarter of 2017, up 24.8% year over year.

        Haemonetics (HAE) Tops Q4 Earnings, Sales, Issues 2018 View

        Haemonetics Corporation (HAE) reported adjusted earnings per share (EPS) of 39 cents in the fourth quarter of fiscal 2017, up 5.4% year over year.

          DENTSPLY (XRAY) Earnings and Revenues Miss Estimates in Q1

          DENTSPLY SIRONA Inc. (XRAY) reported adjusted earnings per share of 49 cents in the first quarter of 2017, missing the Zacks Consensus Estimate by 2 cents.

            Integer (ITGR) Q1 Earnings Miss, Revenues Beat Estimates

            Integer Holdings Corporation (ITGR) reported adjusted earnings of 41 cents per share in the first quarter of 2017, a penny down on a year-over-year basis.

              Phibro (PAHC) Posts In Line Earnings in Q3, Revises View

              Phibro Animal Health Corporation (PAHC) reported adjusted earnings per share (EPS) of 37 cents in the third quarter of fiscal 2017, down 7.5% year over year.

                Align Technology Invisalign Sales Strong, Currency Woes Stay

                On May 5, we issued an updated research report on Align Technology (ALGN), which manufactures a system of clear aligner therapy.

                  Qiagen Banks on Molecular Diagnostic amid Currency Woes

                  On May 4, we issued an updated research report on leading molecular diagnostic company, Qiagen N.V. (QGEN).

                    CVS Down on Weak Earnings, Pharmacy Services Remains Strong

                    On May 5, we issued an updated research report on Rhode Island-based pharmacy retail giant CVS Health Corp. (CVS).

                      Abiomed (ABMD) Q4 Earnings Meet, Revenues Beat Estimates

                      Abiomed posted a promising fourth quarter of fiscal 2017, with revenues beating the Zacks Consensus Estimate and earnings meeting the mark.

                        VWR Corp (VWR) Beats on Q1 Earnings, Awaits Merger Closure

                        VWR Corporation (VWR) reported first-quarter 2017 adjusted earnings per share (EPS) of 44 cents, reflecting a 10% rise from the year-ago quarter.

                          BioScrip (BIOS) Q1 Loss Narrower than Expected, Sales Miss

                          BioScrip, Inc. (BIOS) reported net loss from continuing operations of $19.4 million or a loss of 18 cents per share in the first quarter of 2017 compared with net loss of $9.5 million or a loss of 17 cents a year ago.

                            Allscripts (MDRX) Beats on Q1 Earnings, Revenues In Line

                            Allscripts Healthcare Solutions, Inc. (MDRX) reported first-quarter 2017 earnings of 10 cents per share, beating the Zacks Consensus Estimate by a penny.

                              Omnicell (OMCL) Q1 Loss Narrower than Expected, Revenues Lag

                              Omnicell, Inc. (OMCL) reported a loss per share of 29 cents in first-quarter 2017, reflecting a deterioration from the year-ago loss of a penny.

                                Wright Medical (WMGI) Posts Wider-than-Expected Loss in Q1

                                Wright Medical Group N.V. (WMGI) reported adjusted loss of 9 cents per share in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 8 cents.

                                  PerkinElmer (PKI) Tops Q1 Earnings Estimates, FY17 View Up

                                  PerkinElmer Inc (PKI) reported first-quarter 2017 adjusted earnings of 55 cents per share, marginally beating the Zacks Consensus Estimate by a penny.

                                    athenahealth (ATHN) Earnings, Revenues Miss Estimates in Q1

                                    athenahealth Inc. (ATHN) reported adjusted earnings of 10 cents per share in the first quarter of fiscal 2017.

                                      AmerisourceBergen (ABC) Beats on Q2 Earnings, Lags Revenues

                                      AmerisourceBergen Corporation (ABC) posted adjusted earnings of $1.77 per share in the second quarter of fiscal 2017, beating the Zacks Consensus Estimate of $1.71 and increasing 5.4% on a year-over-year basis.

                                        Cardiovascular Systems (CSII) Swings to Earnings in Q3

                                        Cardiovascular Systems, Inc. (CSII) reported adjusted earnings per share of 3 cents in third-quarter fiscal 2017, reflecting a massive improvement from the year-ago quarter's adjusted loss of 47 cents.

                                          Bruker (BRKR) Q1 Earnings Meet, Revenues Beat Estimates

                                          Bruker Corporation (BRKR) reported adjusted earnings per share (EPS) of 19 cents in the first quarter of 2017, lower than the year-ago figure by 9.5%.

                                            DaVita (DVA) Earnings Miss Estimates, Revenues Beat in Q1

                                            DaVita Inc. (DVA) reported first-quarter 2017 adjusted operating earnings of 79 cents per share that missed the Zacks Consensus Estimate of 82 cents.

                                              QIAGEN (QGEN) Beats Q1 Earnings Estimates, Retains View

                                              QIAGEN N.V. (QGEN) reported first-quarter 2017 adjusted earnings per share (considering restructuring expenses as one time item) of 22 cents, up 15.8% year over year.

                                                DexCom (DXCM) Q1 Loss Narrower than Expected, Revenues Miss

                                                DexCom Inc. (DXCM) reported a loss of 49 cents per share in the first quarter of 2017, narrower than the Zacks Consensus Estimate of a loss of 55 cents.

                                                  Myriad Genetics (MYGN) Tops Q3 Earnings & Sales, Tweaks View

                                                  Myriad Genetics Inc. (MYGN) reported adjusted earnings per share (EPS) of 27 cents in the third quarter of fiscal 2017, down 34% year over year.